Q
QuantAbundanceAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

30,484 signal articles · 140 in last 24h · 154,336 total before filter · latest 1h ago
140last 24h
860last 7d
141● bullish (7d)
96● bearish (7d)
214publishers
AllMacro204Earnings103M&A124Regulatory21Product21Analyst19
✕ clear all filtersticker: CVSSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Eli Lilly Stock on Track for Record as Insurance Coverage Expands for Zepbound
The Wall Street Journal119d agoneutral
Eli Lilly Stock on Track for Record as Insurance Coverage Expands for Zepbound

Eli Lilly shares are on pace to hit a new all-time closing high on news of increased insurance coverage for its blockbuster weight-loss drug Zepbound. Lilly shares were recently up 4.4% to $1,130.90. Pharmacy-benefit manager CVS Caremark decided to add back Lilly’s Zepbound weight-loss drug to its lists of preferred drugs.

Eli Lilly shares edge higher after CVS expands coverage for Zepbound obesity drug (LLY)
InvestorsHub119d agoneutral
Eli Lilly shares edge higher after CVS expands coverage for Zepbound obesity drug (LLY)

Eli Lilly and Company (NYSE:LLY) shares gained about 1% in premarket trading Thursday after CVS Caremark announced it would add the company’s obesity treatment Zepbound to its preferred drug formulary. Lilly said the decision means all three of the largest pharmacy benefit managers in the United States will now provide coverage for the company’s full obesity medicine portfolio.

CVS brings back coverage for Lilly's obesity drug Zepbound
Reuters120d agoneutral
CVS brings back coverage for Lilly's obesity drug Zepbound

May 28 () - CVS Health said on Thursday it will add Eli Lilly's weight-loss drug Zepbound back to some ‌of its drug lists as an additional preferred option ‌for insurance coverage. Caremark, CVS' pharmacy benefit management unit, had dropped Zepbound from coverage ​on July 1 last year, while continuing to reimburse for rival Novo Nordisk's Wegovy after negotiating a more favorable price from the Danish drugmaker.

Cencora nabs ex-CVS exec as new CFO
Healthcare Dive120d agoneutral
Cencora nabs ex-CVS exec as new CFO

Eva Boratto, who spent more than a decade at CVS in a variety of finance roles, will join the drug distributor later this summer, Cencora announced Wednesday.

Here’s What Analysts Are Saying About CVS Health Corporation (CVS)
Insider Monkey121d agoneutral
Here’s What Analysts Are Saying About CVS Health Corporation (CVS)

CVS Health Corporation (NYSE:CVS) is one of the best medical stocks to invest in according to billionaires. Morgan Stanley lifted the price target on CVS Health Corporation (NYSE:CVS) to $106 from $93 on May 14, maintaining an Overweight rating on the shares. CVS Health Corporation (NYSE:CVS) also received a rating update from Bernstein on May 13, […]

3 Overrated  Stocks We’re Skeptical Of
StockStory123d agoneutral
3 Overrated Stocks We’re Skeptical Of

The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.

CVS Health (CVS) Price Target Boosted by $8 at Mizuho
Insider Monkey123d agoneutral
CVS Health (CVS) Price Target Boosted by $8 at Mizuho

With an annual dividend yield of 2.84%, CVS Health Corporation (NYSE:CVS) is included among the 12 Best Dividend Stocks to Invest in According to Hedge Funds. America’s leading health solutions company, CVS Health Corporation (NYSE:CVS) provides advanced health care from pharmacy services and health plans to health and wellness. On May 20, Mizuho bumped up its price […]

Bernstein Sees CVS Well Positioned for Medicare Advantage Turnaround
Insider Monkey125d agoneutral
Bernstein Sees CVS Well Positioned for Medicare Advantage Turnaround

CVS Health Corporation (NYSE:CVS) is included among the 10 High Quality Stocks to Buy According to Hedge Funds. On May 13, Bernstein raised its price recommendation on CVS Health Corporation (NYSE:CVS) to $106 from $94. It reiterated an Outperform rating on the stock. The firm said it still sees CVS as well-positioned to benefit from […]

CVS Health Lawsuits Test 340B Practices And Investor Risk Assessment
Simply Wall St.127d agobearish
CVS Health Lawsuits Test 340B Practices And Investor Risk Assessment

CVS Health (NYSE:CVS) has been hit with two lawsuits from major hospital systems tied to the federal 340B drug discount program. The University of Kansas Hospital Authority and the University of Michigan Hospitals and Health Centers allege CVS Health improperly profited from 340B discounts. Combined claimed damages exceed $60 million, raising legal, financial, and reputational questions for the company. CVS Health comes into this legal pressure with its shares at $93.28 and a return of...